Bacillus Calmette-Guerin (BCG) vaccine is still the only vaccine approved for the prevention of tuberculosis (TB), and is widely used in highly endemic countries, where all newborns receive a single intradermal dose immediately after birth; however, the recommendations concerning its use in Europe vary widely from country to country. This document describes the recommendations of a group of Italian scientific societies concerning its pediatric use in Italy, the persistence of the protection it provides, its safety, its interference with tuberculin skin test (TST) responses, and the children who should be vaccinated. The experts conclude that BCG vaccination provides a good level of protection against tuberculous meningitis and disseminated forms, and a fair level of protection against pulmonary disease; the protective effective lasts at least 10 years, and revaccination offers no advantages over a single administration. The vaccine is safe in immunocompetent subjects, and affects the response to a TST for at least 6 y On the basis of these observations, we recommend its use in Italy in all TST-negative immunocompetent newborns and breastfeeding infants aged <6 months, and all TST-negative children aged between 6 months and 5 y who come from highly epidemic areas, or whose parents come from highly endemic areas, or who have been in contact with a family member with active TB without contracting the disease themselves.

Recommendations for pediatric tuberculosis vaccination in Italy / Montagnani, Carlotta; Esposito, Susanna; Galli, Luisa; Chiappini, Elena; Principi, Nicola; de Martino, Maurizio; Bosis, Samantha; Tagliabue, Claudia; Senatore, Laura; Ascolese, Beatrice; Villani, Alberto; Lancella, Laura; Cursi, Laura; Grandin, Annalisa; Marabotto, Caterina; Galli, Luisa; Chiappini, Elena; Ciofi, Daniele; Festini, Filippo; Anziati, Martina; Becciani, Sabrina; Remaschi, Giulia; Sollai, Sara; Tersigni, Chiara; Venturini, Elisabetta; Guarino, Alfredo; Lo Vecchio, Andrea; Scotto, Riccardo; Gabiano, Clara; Garazzino, Silvia; Le Serre, Daniele; Raffaldi, Irene; Bernardi, Filippo; Bertazzoni, Elisa; Blasi, Francesco; Bocchino, Marialuisa; Assante, Luca; Castagnola, Elio; Losurdo, Giuseppe; Codecasa, Luigi; Di Mauro, Giuseppe; Faccini, Marino; Marseglia, Gianluigi; Mascolo, Amelia; Di Comite, Amelia; Stronati, Mauro; Matteelli, Alberto; Migliori, Giovanni Battista; D’Ambrosio, Lia; Centis, Rosella; Pasinato, Angela; Cirillo, Daniela; Tortoli, Enrico; Russo, Cristina; Scaglione, Franco; Scala, Elisabetta. - In: HUMAN VACCINES & IMMUNOTHERAPEUTICS. - ISSN 2164-5515. - STAMPA. - 12:(2016), pp. 644-650. [10.1080/21645515.2015.1106657]

Recommendations for pediatric tuberculosis vaccination in Italy

MONTAGNANI, CARLOTTA;GALLI, LUISA;CHIAPPINI, ELENA;DE MARTINO, MAURIZIO;GALLI, LUISA;CHIAPPINI, ELENA;CIOFI, DANIELE;FESTINI, FILIPPO;BECCIANI, SABRINA;REMASCHI, GIULIA;SOLLAI, SARA;TERSIGNI, CHIARA;VENTURINI, ELISABETTA;LO VECCHIO, ANDREA;GARAZZINO, SILVIA;CASTAGNOLA, ELIO;MATTEELLI, ALBERTO;TORTOLI, ENRICO;
2016

Abstract

Bacillus Calmette-Guerin (BCG) vaccine is still the only vaccine approved for the prevention of tuberculosis (TB), and is widely used in highly endemic countries, where all newborns receive a single intradermal dose immediately after birth; however, the recommendations concerning its use in Europe vary widely from country to country. This document describes the recommendations of a group of Italian scientific societies concerning its pediatric use in Italy, the persistence of the protection it provides, its safety, its interference with tuberculin skin test (TST) responses, and the children who should be vaccinated. The experts conclude that BCG vaccination provides a good level of protection against tuberculous meningitis and disseminated forms, and a fair level of protection against pulmonary disease; the protective effective lasts at least 10 years, and revaccination offers no advantages over a single administration. The vaccine is safe in immunocompetent subjects, and affects the response to a TST for at least 6 y On the basis of these observations, we recommend its use in Italy in all TST-negative immunocompetent newborns and breastfeeding infants aged <6 months, and all TST-negative children aged between 6 months and 5 y who come from highly epidemic areas, or whose parents come from highly endemic areas, or who have been in contact with a family member with active TB without contracting the disease themselves.
2016
12
644
650
Montagnani, Carlotta; Esposito, Susanna; Galli, Luisa; Chiappini, Elena; Principi, Nicola; de Martino, Maurizio; Bosis, Samantha; Tagliabue, Claudia; ...espandi
File in questo prodotto:
File Dimensione Formato  
khvi-12-03-1106657.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 339.79 kB
Formato Adobe PDF
339.79 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1071348
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact